Delcath Liver Cancer Surge (DCTH)

Posted in pre-market 
April 22nd, 2010

Delcath Systems Inc. (NASDAQ: DCTH) is trading up big this morning.  The company’s Phase III liver cancer study its its primary endpoint and exceeded its endpoint targets.  The market cap at yesterday’s close was $393.7 million and the 52-week trading range was $2.09 to $11.00.  This marks an all-time high as shares are trading up 32% at $14.37 on almost 500,000 shares as of 8:45 AM EST.  Average volume here is 922,000 shares, something which should be passed early this morning.  Be advised that over the last month this one has traded over 1 million shares just about every day.


Comments are closed